Summary To assess the achievement of uniformity of radiobiological effectiveness at different depths in the proton spread-out Bragg peak (SOBP), Chinese hamster ovary (CHO) cells were exposed to 65-MeV modulated proton beams at the Research Center for Nuclear Physics (RCNP) of Osaka University. We selected four different irradiation positions: 2 mm depth, corresponding to the entrance, and 10, 18 and 23 mm depths, corresponding to different positions in the SOBP. Cell survival curves were generated with the in vitro colony formation method and fitted to the linear-quadratic model. With 137CS gamma-rays as the reference irradiation, the relative biological effectiveness (RBE) values for a surviving fraction (SF) level of 0.1 are 1.05, 1.10, 1.12 and 1.19 for depths of 2, 10, 18 and 23 mm respectively. A significant difference was found between the survival curves at 10 and 23 mm (P < 0.05), but not between 18 and 10 mm or between 18 and 23 mm. There was a significant dependence of RBE on depths in modulated proton beams at the 0.1 surviving fraction level (P< 0.05). Moreover, the rise of RBEs significantly depended on increasing SF level or decreased approximately in correspondence with irradiation dose (P = 0.0001). To maintain uniformity of radiobiological effectiveness for the target volume, careful attention should be paid to the influence of depth of beam and irradiation dose.
The depth-dose curve for the single-energy proton beam has limited applications in clinical radiation therapy owing to the excessively narrow high-dose region. This region, also known as the Bragg peak, can be modulated by appropriate selection of a distribution of proton energies to produce a spread-out Bragg peak (SOBP) or a uniform region of full dose at the depth of interest. Dose uniformity across a target volume can be achieved with multiple X-ray beams. However, each X-ray beam features a greater dose in the entrance region than a corresponding proton beam, has a dose gradient across the target volume and delivers an undesirable dose to normal tissues distal to the target. Proton beams have none of these undesirable characteristics (Suit and Urie, 1992; Munzenrider and Crowell, 1994; Raju, 1996) .
Although SOBP produces an excellent physical dose distribution, there is a variation of linear energy transfer (LET) values at different depths in the SOBP, known as the LET gradient, from proximal to distal SOBP. The proton is a lower LET particle than other heavy-charged particles; for example, the mean LET values of the 65-MeV modulated proton beams (SOBP) are always less than 7 keV .m-' (Courdi et al, 1994) .
The achievement of uniformity of radiobiological effectiveness for target volumes is always a matter of concern. In fact, there is no uniformity of LET within target volumes. One study has suggested that DNA double-strand breaks, potentially lethal damage and sublethal damage, depend on LET and are closely between RBE and LET for protons is not clear and only few data are available. However, at LET values ranging from about 6 to 30 keV ,um-', RBE values drastically increase, and reach a peak value at about 30 keV im-' (Belli et al, 1989; 1993; Folkard et al, 1989; Prise et al, 1990 ). We were therefore interested in whether there is a uniformity of radiobiological effectiveness in a relatively poorly understood region. Dose (Gy) Dose (Gy) Figure 2 Survival curves of CHO cells exposed to 65-MeV modulated proton beams. A, B and C show the first, second and third experiments respectively. D represents a composition of the three experiments and is called an SMV curve There are 14 facilities for proton therapy worldwide, and the number of new facilities continues to increase (Raju, 1996) . In 1992, construction was started of the biological and medical port in the azimuthally varying field (AVF) cyclotron of the Research Center for Nuclear Physics (RCNP), Osaka University, Japan. A new port was completed at the RCNP in 1993 and is the first biological and medical port for proton beams developed in western Japan (Ozeki et al, 1994; Murayama et al, 1995; Tang et al, 1996) . Since 1994, we have conducted preclinical experiments as a precursor to future clinical studies (Tang et al, 1996 
Irradiation conditions
Reference irradiation was performed with '37Cs gamma-rays generated by Gammacell 40 Exactor (Nordion International, Canada). The dose rate was 1.27 Gy min-', and doses ranged from Oto 10Gy. The 65-MeV proton beams were generated from the AVF cyclotron of the RCNP. Our proton irradiation system consisted mainly of a beam control unit, a beam-forming unit, a beam monitoring unit and a sample change unit, which included two wobbler magnets, a beam scatterer, a beam viewer, a range shifter, a range modulator, a beam monitor and a sample changer. The range shifter is used for degrading the proton energy and the range modulator for construction of SOBP. Details of the facility have been reported in previous publications (Ozeki et al, 1994; Murayama et al, 1995; Tang et al, 1996) .
The flasks of cell cultures were irradiated in the sample changer unit with a dose rate of approximately 2-4 Gy min-'. The maximum range of depth-dose distribution corresponded to a beam energy of approximately 65 MeV owing to energy loss in beam-shaping devices and in the air. In fact, the energy levels of the proton beams varied from 64.5 MeV to 64.8 MeV during the three experiments. Figure 1 shows the depth-dose profiles and the various positions of irradiation. Survival data of clonogenic cells were obtained for CHO cells irradiated at the 2 mm depth corresponding to the entrance and at 10, 18 and 23-mm depths corresponding to the three different positions in the SOBP.
The dose determination procedure using the ionization chamber follows the recommendations given in the American Association of Physicists in Medicine (AAPM) protocol for heavy-charged particle dosimetry (AAPM, 1986) . The ionization chamber reached from the plateau to the unmodulated Bragg peak region of a monoenergetic beam and the absorbed dose was monitored. When a rotating range modulator was set up at the port, the absorbed dose at the SOBP was also measured.
Data analysis
For analysis, the cell survival data were fitted to the linearquadratic model, whose parameters a and A were calculated by computer. The survival level at a dose of 2 Gy (S2Gy) is claimed to be the conventional parameter of clinical radiation response and was also calculated from the curves of the linear-quadratic model. RBE values were obtained from the survival mean values (SMV) curves of three experiments at survival levels 0.8, 0.67, 0.37, 0.1 and 0.05, which roughly corresponds to 1 Gy, 2 Gy, 4 Gy, 6 Gy and 8 Gy respectively. For the analysis of survival curves, the homogeneity of variances was tested with the F-test. When the variance was homogeneous, one-way analysis of variance (Scheffe F-test of multiple comparison) was applied (Mould, 1994) . The relationship between RBE and surviving fraction (SF) level and depth in the proton beams was tested by the regression method. A P-value of less than 0.05 was considered to be significant.
RESULTS
We carried out three experiments to investigate the radiobiological effectiveness at different depths in 65-MeV modulated proton beams. Survival curves for the first, second and third experiments at the four different depths and with '37Cs gamma-rays are shown in Figures 2A-C respectively. Figure 2D represents a composition (Table 3) . The RBEs were then calculated from SMV curves ( Figure 2D) 1989; Barendsen et al, 1993; 1994b; Hall, 1994) . A report from the Harvard Cyclotron Group showed that an increase in RBE values nodulated proton beams (mm) was related to depth in 160-MeV proton beams SOBP (Robertson n RBE and depth in 65-MeV modulated et al, 1975) . However, the results of other in vivo or in vitro expersof 0.8, 0.67, 0.37, 0.10 and 0.05 using the iments by the same group suggested that RBE in the incident plateau was not significantly different from that in SOBP (Hall et al, 1978; Urano et al, 1980) . Several special studies on this subject have been completed in alled an SMV curve. The radiation Europe during the last few years. In France, human melanoma MV curves are presented in Table 1 . cells were exposed to 65-MeV proton beams, with the results indiaes is seen following an increase in cating the RBE depended on depths in SOBP or changes of LET ton beams, ranging from 0.1993 to (Courdi et al, 1994) . Very recently, the radiation response of the is seen in 1-values. Furthermore, S2Gy CHO cell line to 85-MeV proton beams was tested at four different ase following an increase in depth in SOBP positions, but no significant differences in RBEs at various depths in proton beams were identified (Gueulette et al, 1996) . d was used to establish the SMV These experiments all adopted the typical, universal and accurate fferent depths in proton beams (Table  colony formation method, so that the results cannot be dismissed. ference was found among the four Our data have demonstrated that radiobiological effectiveness rent irradiation depths (P = 0.0001).
strongly depends on depth in 65-MeV proton beams, and therefore s indicated that the survival curve at agree with the results of the French study. Thus, the universal er than those at 2 and 10 mm, but not CHO cell line was used in our experiments but not a sensitive or {as no significant difference between non-sensitive cell line. Because the character of different depths in mm.
proton beams is actually related to changes in LET (Courdi et al, Is at four different depths compared 1994, Gueulette et al, 1996) , the radiobiological effectiveness can a-ray was calculated at SF levels of be considered to depend on LET.
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Our data also show that there is no significant difference between survival curves at depths of 18 and 10 mm or of 18 and 23 mm. However, a significant difference was observed between survival curves of 10 and 23 mm. These results suggest that radiobiological effectiveness depends on depths in proton beams. If the proton beams are used to irradiate tumours, importance must be attached to uniformity of radiobiological effectiveness within target volumes. Because the SOBP used in clinical therapy is larger than the experimental SOBP, research into, and discussion of, the uniformity of radiobiological effectiveness at different depths in SOBP used for clinical therapy should be continued. In the meantime, when planning radiotherapy, we should exhaust every possible means to maintain uniform distribution of radiobiological effectiveness within target volumes.
We compared changes in RBE values at the SF level of 0.8, 0.67, 0.37, 0.10 and 0.05, which roughly corresponds to I-Gy, 2-Gy, 4-Gy, 6-Gy and 8-Gy fractions. (Hall et al, 1978; Cucinotta et al, 1991; Blomquist et al, 1993) . Blomquist et al (1993) obtained a high RBE value of 1.63 at the 0.5 SF level compared with 1.28 and 1.15 at the 0.1 and 0.01 SF level in V79-379A cells. Urano et al (1980) considered the significance of these differences to be unclear, and it may be the cause of experimental error or other error. One study analysed the phenomenon using the cellular track model. It was found that, at high dose, proton-produced damage was similar to that produced by gamma-rays. On the other hand, at low dose, the radiobiological effectiveness of proton was very different from that of gamma-rays (Cucinotta et al, 1991) . There have also been other studies that did not definitely support the difference (Yashkin et al, 1995; Gueulette et al, 1996) . We found a definite correlation between RBE and SF level or irradiation dose. As the relationship between RBE and irradiation dose is very important in the radiotherapy field, further research is needed.
Accurate determination of RBE is required in radiation therapy as a dose variation of 5% can be detected in some clinical situations (Menzel et al, 1987) . This is especially true for proton beam therapy because high doses are often prescribed for target volumes close to, or adjacent to, critical radiosensitive normal structures. As the dose prescribed for a patient is directly related to the selected clinical RBE, an accuracy of 5% is also required for the determination of the RBE (Gueulette et al, 1996) . Our data showed that RBEs, at the 0.1 SF level, corresponding to the 6-Gy fraction region, are 1.10, 1.12 and 1.19 at depths of 10, 18 and 23 mm respectively. The differences in RBEs were less than 5% between 18 and 10 mm, but were greater than 5% between 10 and 23 mm and between 18 and 23 mm. Moreover, at the 0.67 SF level, corresponding to the 2-Gy fraction region, RBE values of 1.19, 1.23 and 1.37 were obtained at depths of 10, 18 and 23 mm respectively. The differences in RBE values at the 0.67 SF level were more than 10%. Thus, differences of more than 10% may result in serious problems of non-uniform radiobiological effectiveness in target volumes. The non-uniform distribution of radiobiological effectiveness may in fact be directly related to the non-control and recurrence of some tumours, and has great significance for clinical radiotherapy. Therefore, we should pay careful attention to obtaining an accuracy of 5% in RBE in clinical radiotherapy.
Although this study involved in vitro experiments, the results should help current clinical therapy, as the results of studies of radiobiological effectiveness are universal. On the other hand, the absolute value of RBE may, to some extent, depend on the tissue, cell line or experimental end point (Urano et al, 1980) . Actual and individual data are the most important for any facility. To identify common characteristics, other cell lines and tissues should be evaluated for uniformity of radiobiological effectiveness at different facilities.
CONCLUSIONS
This study of radiation responses at the RCNP AVF cyclotron's biological and medical port with CHO cells exposed to 65-MeV modulated proton beams compared with 137Cs gamma-rays led to the following conclusions: 
